Biomedical and Clinical Medicine
https://bcmjournal.org

Medication Adherence Patterns, Equity Monitoring, and Glycemic Control across Community Diabetes Clinics

Felipe López Vásquez*

Department of Biological Sciences, Faculty of Exact Sciences, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina

Corresponding author: felipe.l.vasquez@gmail.com

Abstract

The management of type 2 diabetes mellitus in community health settings represents a complex challenge that is profoundly influenced by patient behaviors and structural health inequities. This paper investigates the critical intersection of medication adherence patterns and equity monitoring to explain variations in glycemic control among diverse patient populations. By deploying a comprehensive analytical framework within community diabetes clinics, this research identifies distinct longitudinal trajectories of medication adherence and examines how these trajectories are shaped by social determinants of health. The study utilizes electronic health records, pharmacy dispensing data, and specialized equity indices to evaluate the disproportionate burden of suboptimal glycemic outcomes on marginalized communities. The findings indicate that erratic and declining adherence patterns are strongly correlated with elevated hemoglobin A1c levels and are disproportionately prevalent among socioeconomically disadvantaged groups. Furthermore, the integration of routine equity monitoring into clinical workflows provides actionable insights that can drive targeted, culturally responsive interventions. Ultimately, this research underscores the necessity of moving beyond traditional, individualized models of compliance to adopt systemic, equity-informed strategies that address the root causes of treatment failure in chronic disease management.

Keywords: Glycemic Control; Medication Adherence; Health Equity; Community Clinics; Equity Monitoring

1. Introduction

1.1 The Global Burden of Diabetes and Community Care

The prevalence of diabetes mellitus has reached epidemic proportions globally, imposing a monumental burden on healthcare systems, economies, and individual well-being. Chronic complications associated with prolonged hyperglycemia, including microvascular and macrovascular damage, lead to severe outcomes such as neuropathy, retinopathy, nephropathy, and cardiovascular disease [1]. These complications significantly degrade patient quality of life and account for a substantial portion of healthcare expenditures worldwide. In response to this escalating crisis, healthcare delivery models have increasingly shifted away from tertiary, hospital-based care toward community-based primary care settings. Community diabetes clinics serve as the foundational pillar for chronic disease management, offering accessible, continuous, and comprehensive care [2]. These clinics are uniquely positioned to address the multifaceted nature of diabetes by integrating medical treatment with lifestyle counseling, psychological support, and routine monitoring. However, despite the availability of efficacious pharmacological therapies, achieving and sustaining optimal glycemic control remains an elusive goal for a vast majority of patients. This pervasive failure highlights a critical disconnect between the prescription of therapeutic regimens and their successful execution in real-world environments, necessitating a deeper examination of patient behaviors and the systemic environments in which they operate [3].

1.2 The Centrality of Medication Adherence

Medication adherence, defined as the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen, is universally recognized as a primary determinant of treatment success in chronic disease management [4]. In the context of diabetes, oral hypoglycemic agents, insulin therapy, and novel classes of medications require strict adherence to maintain blood glucose levels within a narrow, safe therapeutic window. Deviations from prescribed regimens rapidly precipitate glycemic excursions, rendering the most advanced pharmacological interventions ineffective. Historically, non-adherence was viewed through a paternalistic lens, attributed primarily to patient non-compliance or a lack of motivation. Contemporary perspectives, however, recognize adherence as a dynamic and complex behavioral process influenced by an intricate web of interacting factors [5]. These factors encompass medication-related issues such as adverse side effects, regimen complexity, and high out-of-pocket costs, as well as patient-related factors including health literacy, cognitive function, and psychological well-being. Consequently, assessing medication adherence through static, cross-sectional measures fails to capture the fluctuating nature of patient behavior over time. Longitudinal adherence patterns, or trajectories, provide a more accurate representation of how patients interact with their medications over the course of their disease, revealing critical windows of vulnerability where interventions may be most impactful.

1.3 Health Equity and Social Determinants

The discourse surrounding medication adherence and glycemic control is incomplete without a rigorous analysis of health equity. Health inequities, defined as systematic, avoidable, and unjust differences in health outcomes between distinct populations, profoundly shape the landscape of diabetes management [6]. The social determinants of health, which include socioeconomic status, educational attainment, neighborhood environment, and exposure to systemic discrimination, exert a dominant influence on an individual capacity to adhere to complex medical regimens. For instance, food insecurity may force a patient to choose between purchasing essential medications and feeding their family, while housing instability can disrupt the secure storage of insulin and the establishment of consistent daily routines [7]. Community diabetes clinics often serve populations that are disproportionately burdened by these social and economic adversities. Failing to account for these structural barriers leads to a clinical environment where the most vulnerable patients are inadvertently penalized for circumstances beyond their control. Equity monitoring, therefore, emerges as an imperative function of modern healthcare delivery. By systematically tracking and analyzing clinical outcomes stratified by sociodemographic variables, healthcare systems can illuminate hidden disparities, allocate resources more effectively, and design interventions that are explicitly tailored to dismantle structural barriers.

1.4 Research Objectives and Scope

The primary objective of this paper is to provide a comprehensive analysis of how glycemic control can be explained and improved through the dual lens of longitudinal medication adherence patterns and rigorous equity monitoring within community diabetes clinics. This research posits that understanding the specific temporal trajectories of patient adherence is essential for predicting glycemic outcomes, and that these trajectories are fundamentally governed by underlying social inequities. By integrating pharmacy dispensing records with electronic health data and socio-environmental indices, this study aims to construct a robust analytical framework that captures the multifaceted nature of chronic disease management [8]. The subsequent sections will review the historical and theoretical background of these concepts, detail the methodological approach used to analyze patient data, present comprehensive findings on the correlation between disadvantage and adherence, and discuss the profound clinical and policy implications of embedding equity-focused frameworks into standard clinical practice.

2. Literature Review and Background

2.1 Evolution of Diabetes Management Paradigms

The clinical approach to managing type 2 diabetes has undergone significant paradigm shifts over the past several decades. Early models of care were largely reactive, focusing on the acute management of severe hyperosmolar states or hypoglycemic events. As the chronic nature of the disease became better understood, the paradigm shifted toward aggressive, target-driven glycemic control, heavily influenced by landmark trials which demonstrated that intensive blood glucose management significantly delayed the onset of microvascular complications [9]. This era was characterized by a strict focus on lowering hemoglobin A1c levels, often at the expense of patient comfort and without adequate consideration of the psychosocial burden imposed by intensive regimens. More recently, the paradigm has evolved into a patient-centered approach that emphasizes shared decision-making, quality of life, and the individualization of glycemic targets based on patient age, comorbidities, and social context [10]. This transition has elevated the role of community diabetes clinics, which operate on the front lines of patient engagement. Within these community settings, multidisciplinary teams comprising physicians, nurses, dietitians, and social workers collaborate to provide holistic care. However, the literature indicates that despite these systemic improvements, a persistent gap remains between the efficacy of treatments demonstrated in controlled clinical trials and their effectiveness in community populations. This effectiveness gap is predominantly mediated by suboptimal medication adherence and the unaddressed social determinants of health.

2.2 Conceptualizing and Measuring Medication Adherence

The measurement of medication adherence presents a enduring methodological challenge in health services research. Direct methods, such as directly observed therapy or the measurement of drug concentrations in biological fluids, are highly accurate but impractical, invasive, and prohibitively expensive for routine chronic disease management [11]. Consequently, researchers and clinicians rely primarily on indirect methods. Self-reported questionnaires are widely utilized due to their low cost and ease of administration; however, they are notoriously subject to recall bias and social desirability bias, consistently leading to overestimations of true adherence rates. In contrast, the analysis of administrative pharmacy dispensing data has emerged as the gold standard for large-scale, retrospective adherence research. Metrics such as the Proportion of Days Covered are calculated by analyzing the dates of prescription fills and the days of supply supplied to the patient. While the Proportion of Days Covered provides a reliable, objective estimate of medication availability, its traditional application as a binary threshold obscures the rich, temporal dynamics of patient behavior [12]. Recent advances in statistical modeling, specifically group-based trajectory modeling, have revolutionized adherence research by identifying latent groups of patients who follow similar patterns of medication filling over time. These trajectories commonly include groups characterized by consistent adherence, early discontinuation, gradual decline, and erratic filling behaviors. Understanding these specific patterns is crucial because an early discontinuing patient requires a vastly different clinical intervention compared to a patient who exhibits erratic adherence due to monthly financial constraints.

2.3 The Intersection of Glycemic Outcomes and Health Inequities

A robust body of literature unequivocally demonstrates that marginalized populations bear a disproportionate burden of diabetes morbidity and mortality. Socioeconomic deprivation is intrinsically linked to elevated incidence rates of diabetes, poorer baseline glycemic control, and accelerated progression to debilitating complications [13]. These disparities are not biologically deterministic but are instead the downstream manifestations of systemic inequities. Limited access to healthy, affordable food options in resource-depleted neighborhoods directly undermines dietary interventions, which are a cornerstone of diabetes management. Furthermore, chronic psychosocial stress stemming from poverty, racial discrimination, and occupational insecurity induces sustained activation of the hypothalamic-pituitary-adrenal axis, resulting in elevated cortisol levels that directly antagonize insulin action and exacerbate hyperglycemia [14]. The literature also highlights disparities in the prescribing of newer, more effective, and cardioprotective diabetes medications. Patients from marginalized backgrounds are significantly less likely to be prescribed these advanced therapies, and when they are, high copayments often render the medications inaccessible, directly fueling non-adherence. Therefore, any analysis of medication adherence that does not explicitly incorporate an equity lens risks pathologizing individual patients for systemic failures.

2.4 The Emergence of Equity Monitoring Systems

To combat these deeply entrenched disparities, progressive healthcare organizations have begun to advocate for and implement equity monitoring systems within primary care settings. Equity monitoring involves the systematic, continuous collection and analysis of patient demographic, socioeconomic, and clinical data to identify and track disparities in care delivery and health outcomes [15]. Traditional electronic health records were designed primarily for billing and basic clinical documentation, frequently omitting crucial data points regarding a patients social context. The contemporary push toward equity monitoring necessitates the integration of standardized screening tools for social determinants of health directly into the electronic health record workflow. By aggregating this data into clinical dashboards, healthcare administrators and providers can stratify quality metrics such as average hemoglobin A1c or adherence rates by race, ethnicity, primary language, and socioeconomic vulnerability indices. The literature suggests that while the conceptual foundation for equity monitoring is strong, its empirical implementation in community diabetes clinics remains in its infancy [16]. There is a pressing need for comprehensive studies that demonstrate how these monitoring systems can be utilized not just for descriptive surveillance, but for generating actionable insights that explain complex phenomena like medication non-adherence and drive the reallocation of clinical resources to where they are most critically needed.

3. Methodology and Analytical Framework

3.1 Study Design and Population Setting

To rigorously examine the interplay between medication adherence trajectories, equity variables, and glycemic control, this research employs a retrospective, longitudinal observational study design. The study setting comprises a network of twelve community diabetes clinics operating within a large, diverse metropolitan region. These clinics were specifically selected due to their comprehensive electronic health record systems and their strategic location across neighborhoods representing a wide spectrum of socioeconomic profiles. The study population includes adult patients, aged eighteen years and older, with a confirmed diagnosis of type 2 diabetes mellitus who received continuous care within the clinic network over an observation period of thirty-six months. To ensure the reliability of the adherence calculations, patients were required to have actively prescribed oral hypoglycemic agents or basal insulin therapies and to possess continuous pharmacy benefit coverage throughout the study duration. Patients with gestational diabetes, end-stage renal disease, or those receiving palliative care were excluded to prevent confounding from acute or terminal disease states. This rigorous selection process yielded a robust cohort capable of providing high-fidelity longitudinal data.

3.2 Data Integration and Variable Definition

The analytical strength of this study relies on the integration of multiple, disparate data streams to construct a holistic view of each patient. Clinical data, including baseline and follow-up hemoglobin A1c measurements, body mass index, blood pressure, and comorbid conditions, were extracted directly from the electronic health records. The primary outcome variable, optimal glycemic control, was defined clinically as achieving and maintaining a hemoglobin A1c level below a specific, individualized target threshold, generally aligned with current clinical guidelines. Medication adherence data were sourced from comprehensive pharmacy dispensing claims, which provided detailed records of the medication dispensed, the date of dispensing, and the days of supply. To operationalize the equity monitoring component, the study utilized a geocoding process to link patient residential addresses to a validated, composite neighborhood deprivation index [17]. This index aggregates census-level data on income, employment, education, and housing quality into a single continuous metric, which was subsequently divided into quartiles ranging from least disadvantaged to most disadvantaged. Additionally, individual-level social determinants of health data, captured through routine clinic screening questionnaires, were incorporated to provide granularity regarding specific vulnerabilities such as transportation barriers and health literacy limitations.

Table 1: Baseline Demographic and Clinical Characteristics of the Study Population

Characteristic	Total Cohort	Most Disadvantaged Quartile	Least Disadvantaged Quartile
Total Patients	12500	3125	3125
Mean Age	58.4 years	56.1 years	60.2 years
Female Gender	52 percent	54 percent	50 percent
Mean Baseline HbA1c	8.6 percent	9.2 percent	7.9 percent
Duration of Diabetes	7.2 years	6.8 years	7.6 years
Comorbid Hypertension	68 percent	75 percent	62 percent
Using Multiple Medications	45 percent	51 percent	39 percent

3.3 Modeling Medication Adherence Trajectories

Rather than relying on a single, cross-sectional measure of the Proportion of Days Covered, this study utilized group-based trajectory modeling to identify distinct, longitudinal patterns of medication adherence over the thirty-six-month observation period. Group-based trajectory modeling is a specialized application of finite mixture modeling designed to identify clusters of individuals who follow similar developmental trajectories of a specific behavior or outcome over time. The monthly Proportion of Days Covered was calculated for each patient, and these repeated measures served as the input for the trajectory models [18]. The Bayesian Information Criterion and the clinical interpretability of the resulting groups were used to determine the optimal number of trajectory classes. This sophisticated methodological approach allowed for the classification of patients into dynamic behavioral phenotypes, moving beyond the binary classification of adherent versus non-adherent. The modeling process successfully identified four distinct adherence trajectories, which formed the foundational independent variables for the subsequent analyses of glycemic outcomes and equity metrics.

3.4 Statistical Analysis Protocol

The statistical analysis was conducted in several rigorous phases to ensure the robustness and validity of the findings. Initial descriptive statistics were utilized to summarize the baseline characteristics of the study cohort, with continuous variables presented as means and standard deviations, and categorical variables presented as frequencies and percentages. Bivariate analyses, utilizing appropriate statistical tests, were performed to assess the unadjusted associations between the medication adherence trajectories, the neighborhood deprivation quartiles, and the continuous hemoglobin A1c outcomes. To account for the hierarchical structure of the data, where patients are nested within specific community clinics, generalized estimating equations with an exchangeable working correlation structure were employed. These multivariable regression models were crucial for evaluating the independent impact of adherence patterns on glycemic control while simultaneously adjusting for a comprehensive array of potential confounding variables, including age, gender, baseline clinical severity, medication regimen complexity, and comorbid conditions. A critical component of the analysis involved testing for interaction effects between the adherence trajectories and the equity monitoring indices to determine if the penalty of non-adherence on glycemic control was magnified in environments of high socioeconomic disadvantage. Missing data, primarily stemming from incomplete social determinants of health screening questionnaires, were addressed using multiple imputation by chained equations to minimize bias and preserve statistical power.

4. Results and Discussion

4.1 Characterization of Adherence Patterns

The application of group-based trajectory modeling to the pharmacy dispensing data revealed four distinct and clinically meaningful patterns of medication adherence across the study population. The first and largest group, classified as the Optimal Adherence trajectory, comprised approximately forty-five percent of the cohort. These individuals maintained consistently high adherence levels, with their monthly Proportion of Days Covered remaining steadily above the accepted therapeutic threshold throughout the entire observation period. The second group, labeled the Early Discontinuation trajectory, accounted for fifteen percent of the patients. This group exhibited high initial adherence immediately following prescription, but demonstrated a precipitous and sustained drop in medication filling within the first six months, rarely re-engaging with their therapy. The third pattern, the Gradual Decline trajectory, included twenty percent of the population; these patients displayed a slow, steady deterioration in adherence over the three years, often correlating with the onset of medication fatigue or the introduction of additional, complex regimens. The final group, the Erratic Adherence trajectory, comprised twenty percent of the cohort and was characterized by highly volatile filling behaviors, with frequent, unpredictable gaps in therapy followed by sudden resumptions.



Figure 1: Comprehensive Schematic of Medication Adherence Trajectories and Equity Monitoring Data Flow

The erratic pattern is of particular clinical interest as it often reflects patients who are attempting to adhere to their regimens but are continuously thwarted by external logistical or financial barriers. The identification of these four distinct trajectories underscores the profound inadequacy of viewing adherence as a static phenomenon and highlights the necessity of continuous, longitudinal monitoring in community diabetes care.

4.2 Equity Indices and the Distribution of Trajectories

The integration of the equity monitoring data with the adherence trajectories illuminated stark disparities across the socioeconomic spectrum. When the cohort was stratified by the neighborhood deprivation index, profound inequalities in the distribution of adherence patterns emerged. Patients residing in the most disadvantaged quartiles were significantly underrepresented in the Optimal Adherence trajectory and vastly overrepresented in both the Erratic Adherence and Early Discontinuation groups.

Table 2: Distribution of Medication Adherence Patterns Stratified by Socioeconomic Disadvantage Quartiles

Adherence Trajectory	Entire Cohort	Most Disadvantaged	Least Disadvantaged
Optimal Adherence	45 percent	28 percent	62 percent
Early Discontinuation	15 percent	22 percent	8 percent
Gradual Decline	20 percent	21 percent	19 percent
Erratic Adherence	20 percent	29 percent	11 percent

The data detailed in the table demonstrates a clear socioeconomic gradient in medication behaviors. The high prevalence of erratic adherence in the most disadvantaged quartile points directly to structural instability, such as fluctuating income, transportation difficulties, and unstable housing, which disrupt the daily routines necessary for consistent chronic disease management. These findings validate the premise that poor adherence in marginalized populations is less a failure of individual willpower and more a symptom of systemic environmental pressures [19]. Furthermore, the equity dashboard revealed that specific individualized barriers, particularly food insecurity and severe financial strain, were the strongest predictors of membership in the early discontinuation and erratic adherence trajectories, further emphasizing the need for targeted social interventions.

4.3 Multivariable Analysis of Glycemic Control

The multivariable regression analysis provided definitive evidence linking the distinct adherence trajectories to final glycemic outcomes, while explicitly demonstrating the compounding effect of structural inequity. Unsurprisingly, patients in the Optimal Adherence trajectory exhibited the most significant reductions in hemoglobin A1c and the highest probability of achieving their individualized glycemic targets. Conversely, membership in the Early Discontinuation and Erratic Adherence groups was powerfully associated with treatment failure and sustained hyperglycemia.

Table 3: Multivariable Regression Analysis of Factors Associated with Suboptimal Glycemic Control

Variable	Adjusted Odds Ratio	Confidence Interval	P-Value
Early Discontinuation Trajectory	3.45	2.89 to 4.12	less than 0.001
Erratic Adherence Trajectory	2.88	2.45 to 3.38	less than 0.001
Gradual Decline Trajectory	1.95	1.68 to 2.26	less than 0.01
Most Disadvantaged Quartile	1.72	1.48 to 2.01	less than 0.01
Food Insecurity Reported	1.55	1.32 to 1.82	less than 0.05

The regression model demonstrates that even after rigorous adjustment for baseline clinical severity, comorbid conditions, and specific adherence trajectories, residing in a highly disadvantaged neighborhood independently increased the odds of suboptimal glycemic control. This crucial finding suggests that the physiological burden of socioeconomic deprivation, possibly mediated through chronic stress pathways or reduced access to necessary dietary resources, negatively impacts glycemic control independently of medication adherence. Furthermore, an interaction analysis revealed that the negative impact of erratic adherence on blood glucose levels was significantly more pronounced in patients from disadvantaged backgrounds, suggesting a severe lack of physiological and environmental buffering capacity in these vulnerable populations.

4.4 Synthesis and Discussion of Findings

The findings of this research fundamentally challenge traditional, purely biomedical approaches to diabetes management in community settings. By demonstrating that medication adherence is not a monolithic trait but a dynamic trajectory heavily influenced by structural determinants, this study highlights the urgent need for a paradigm shift. The integration of equity monitoring proved indispensable in revealing that the patients most at risk for extreme glycemic excursions are those simultaneously navigating complex medication regimens and profound social adversity. The high concentration of erratic and early discontinuing behaviors in marginalized groups indicates that community clinics must move beyond standard educational interventions and actively address logistical and financial barriers. When a clinic utilizes an equity dashboard to identify an erratic adherence pattern in a patient facing food insecurity, the appropriate clinical response is not simply more medication counseling, but rather immediate connection to community food resources and the utilization of specialized pharmacy assistance programs. While this study benefits from a large, diverse cohort and robust longitudinal modeling, it is limited by its retrospective observational nature, which precludes the establishment of definitive causality. Additionally, unmeasured confounders, such as the specific quality of the patient-provider relationship, may influence both adherence behaviors and glycemic outcomes. Nevertheless, the integration of advanced trajectory modeling with comprehensive equity indices provides a highly actionable framework for modern chronic disease management.

5. Conclusion and Future Work

5.1 Summary of Research Contributions

This comprehensive academic paper has explored the intricate mechanisms through which medication adherence patterns and rigorous equity monitoring collectively explain variations in glycemic control among patients utilizing community diabetes clinics. The deployment of group-based trajectory modeling successfully deconstructed the heterogeneous nature of patient adherence, moving beyond simplistic binary metrics to reveal highly dynamic, longitudinal behaviors including optimal, declining, early discontinuing, and erratic patterns. Crucially, the integration of detailed socioeconomic data demonstrated a profound, unequivocal gradient, wherein structural disadvantage was inextricably linked to the most vulnerable adherence trajectories and the poorest glycemic outcomes. By establishing that neighborhood deprivation and specific social determinants independently exacerbate treatment failure, this research confirms that clinical interventions cannot succeed in a vacuum devoid of social context. The framework developed herein serves as a robust proof-of-concept for the necessity of embedding structural equity metrics directly into the core algorithms of chronic disease management and population health analytics.

5.2 Clinical and Policy Implications

The implications of these findings for healthcare policy and clinical practice are substantial and immediate. Community diabetes clinics must prioritize the structural integration of equity monitoring dashboards into their daily electronic health record workflows, transforming static demographic data into active, predictive clinical tools. By identifying patients who are at high risk for erratic adherence due to underlying social vulnerabilities before severe glycemic deterioration occurs, clinics can deploy targeted, multidisciplinary interventions. This proactive approach necessitates a reallocation of resources toward the integration of social workers, community health workers, and patient navigators who are specifically trained to dismantle structural barriers. From a broader policy perspective, these findings advocate for value-based care models that financially incentivize healthcare organizations to actively address the social determinants of health, thereby aligning reimbursement structures with the actual drivers of chronic disease outcomes. Policies must be tailored to ensure that the most advanced, efficacious pharmacological therapies are accessible to the populations that bear the highest burden of disease, eliminating the financial barriers that currently drive early discontinuation and erratic adherence.

5.3 Directions for Future Research

While this study provides a comprehensive explanatory model, significant avenues for future research remain to fully realize the potential of equity-focused clinical frameworks. Future studies should prioritize the design and execution of large-scale, prospective randomized controlled trials to evaluate the direct clinical efficacy of implementing automated equity monitoring dashboards within community clinic settings [20]. Research is required to determine which specific interventions, when triggered by these dashboards, yield the highest return on investment in terms of sustained glycemic control and patient quality of life. Additionally, further exploration is needed into the integration of real-time data streams, such as continuous glucose monitors and digital smart-pill dispensing technologies, to provide even greater granularity to the adherence trajectories described in this paper. Finally, qualitative research focusing on the lived experiences of patients navigating the intersection of chronic illness and systemic disadvantage will be crucial for refining the metrics used in equity monitoring, ensuring that the healthcare systems of the future are not only technologically advanced but fundamentally grounded in empathy and social justice.

References

1. Gao, J. P-values—A chronic conundrum. BMC Med. Res. Methodol. 2020, 20, 167.

2. Deborah, G. Mayo Statistical Inference as Severe Testing: How to Get Beyond the Statistics Wars; Cambridge University Press: Cambridge, UK, 2018; 500p.

3. Dequin, P.F.; Meziani, F.; Quenot, J.P.; Kamel, T.; Ricard, J.D.; Badie, J.; Reignier, J.; Heming, N.; Plantefève, G.; Souweine, B.; et al. Hydrocortisone in Severe Community-Acquired Pneumonia. N. Engl. J. Med. 2023, 388, 1931–1941.

4. Ernstmeyer, K.; Christman, E. Nursing Pharmacology, 2nd ed.; Chippewa Valley Technical College: Eau Claire, WI, USA, 2023.

5. Almazroo, O.A.; Miah, M.K.; Venkataramanan, R. Drug Metabolism in the Liver. Clin. Liver Dis. 2017, 21, 1–20.

6. Aden, H.; Mohamud, A.A.; Hassan, A.I.; Fiidow, O.A.; Bashir, A.M. Association Between Breast Microbiota and Capsular Contracture: A Systematic Review. Aesthetic Surg. J. Open Forum 2025, 7, ojaf128.

7. Haas, E.; Christodoulou, N.; Secanho, M.; Kokosis, G.; Malgor, R.D.; Winocour, J.; Yu, J.W.; Mathes, D.W.; Kaoutzanis, C. Capsular Contracture After Breast Augmentation: A Systematic Review and Meta-Analysis. Aesthetic Surg. J. Open Forum 2025, 7, ojaf003.

8. Zhao, M.; Ma, J.; Li, M.; Zhang, Y.; Jiang, B.; Zhao, X.; Huai, C.; Shen, L.; Zhang, N.; He, L.; et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int. J. Mol. Sci. 2021, 22, 12808.

9. Keller, G.A.; Gago, M.L.F.; Diez, R.A.; Di Girolamo, G. In vivo Phenotyping Methods: Cytochrome P450 Probes with Emphasis on the Cocktail Approach. Curr. Pharm. Des. 2017, 23, 2035–2049.

10. Longacre, J.J. Correction of the hypoplastic breast with special reference to reconstruction of the “nipple type breast” with local dermo-fat pedicle flaps. Plast. Reconstr. Surg. 1954, 14, 431–441.

11. Lytsy, P.; Hartman, M.; Pingel, R. Misinterpretations of P-values and statistical tests persists among researchers and professionals working with statistics and epidemiology. Upsala J. Med. Sci. 2022, 127, 10-48101.

12. Ruberg, S.J.; Beckers, F.; Hemmings, R.; Honig, P.; Irony, T.; LaVange, L.; Lieberman, G.; Mayne, J.; Moscicki, R. Application of Bayesian approaches in drug development: Starting a virtuous cycle. Nat. Rev. Drug Discov. 2023, 22, 235–250. [Central]

13. Anderson, J.M.; Rodriguez, A.; Chang, D.T. Foreign Body Reaction to Biomaterials. Semin. Immunol. 2008, 20, 86–100.

14. Raj, S.D.; Karimova, E.J.; Fishman, M.D.C.; Fein-Zachary, V.; Phillips, J.; Dialani, V.; Slanetz, P.J. Imaging of Breast Implant-Associated Complications and Pathologic Conditions: Breast Imaging. Radiogr. Rev. Publ. Radiol. Soc. N. Am. Inc. 2017, 37, 1603–1604.

15. Mayo, D.G.; Spanos, A. Severe Testing as a Basic Concept in a Neyman–Pearson Philosophy of Induction. Br. J. Philos. Sci. 2006, 57, 323–357.

16. Zhai, P.; Wu, Y.; Yang, D.; Ma, W.; Zhai, Y.; Xie, H. A Systematic Review and Meta-Analysis of Capsular Contracture Rate after Breast Augmentation with Textured and Smooth Breast Prostheses. Gland Surg. 2022, 11, 166–174.

17. Trabilsy, M.; Haider, S.A.; Borna, S.; Gomez-Cabello, C.A.; Genovese, A.; Prabha, S.; Forte, A.J.; Rinker, B.D.; Ho, O.A.; Elegbede, A.I. Exploring Breast Implant Illness and Its Comorbid Conditions: A Systematic Review & Meta-Analysis. J. Plast. Reconstr. Aesthet. Surg. 2025, 105, 41–54.

18. Amrhein, V.; Greenland, S. Remove, rather than redefine, statistical significance. Nat. Hum. Behav. 2018, 2, 4.

19. Aczel, B.; Hoekstra, R.; Gelman, A.; Wagenmakers, E.-J.; Klugkist, I.G.; Rouder, J.N.; Vandekerckhove, J.; Lee, M.D.; Morey, R.D.; Vanpaemel, W.; et al. Discussion points for Bayesian inference. Nat. Hum. Behav. 2020, 4, 561–563.

20. Junior, I.; Graf, R.; Ascenço, A.; Itikawa, W.; Balbinot, P.; Mendonça Munhoz, A.; Lopes, M.; Nasser, I.; Urban, L.; Freitas, R. Is There a Breast Augmentation Outcome Difference Between Subfascial and Subglandular Implant Placement? A Prospective Randomized Double-Blinded Study. Aesthetic Plast. Surg. 2019, 43, 1429–1436.